Prevail InfoWorks

The Radioligand Race Heats Up: Precision Oncology in Action as Sanofi’s AlphaMedix Hits Its Phase 2 Goal Sanofi’s foray into radioligand therapy is starting to look like a smart move. The company’s targeted alpha therapy, Alphamedix, just met key endpoints in a phase 2 study for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)  showing both clinically meaningful activity and a manageable safety profile. For a company that only entered the radioligand space a year ago with a $110M deal, this marks an important step in expanding the role of alpha-emitting radiopharmaceuticals in oncology. Key takeaways:  -AlphaMedix, acquired from Radiomedix, Inc. and Orano Med, targets somatostatin receptors commonly expressed in neuroendocrine tumors.  -Sanofi paid €100M upfront (≈$110M) and committed up to €220M in milestones for the program.  -The phase 2 trial met primary endpoints for overall response rate and safety in 61 patients.  -Progression-free and overall survival data showed “benefits observed” across both pretreated and treatment-naïve cohorts. Radioligand therapies have long been dominated by beta emitters like Lutathera. Sanofi’s data could signal the start of a new wave powered by alpha-emitting isotopes with higher energy and shorter tissue range for more selective tumor cell killing. “The promising AlphaMedix-02 results represent a significant step forward, reinforcing the potential of targeted alpha therapy to deliver precise treatment for GEP-NETs,” Christopher Corsico, M.D., global head of development at Sanofi, said in an Oct 8 release. Could AlphaMedix’s early success accelerate broader adoption of targeted alpha therapy in oncology pipelines? How might Sanofi’s results reshape competition in the fast-growing radioligand field? Read the full article in the comment section #RadioligandTherapy #OncologyInnovation #AlphaTherapy #NeuroendocrineTumors #Sanofi #RadioMedix #OranoMed #PrecisionOncology #DrugDevelopment #Prevail #PrevailInfoWorks 

Are You in Boston for OCT New England 2025? Unlock Smarter Clinical Trials with Prevail InfoWorks Clinical trial operations are evolving fast, and so are the technologies driving them. At the 17th Annual Outsourcing in Clinical Trials New England on October 15–16 at Encore Boston Harbor, the focus will be on clinical operations, outsourcing, rare diseases, innovation, and patient engagement. If you are attending, stop by booth 86 to explore how Prevail InfoWorks is helping biotech and pharmaceutical companies gain real-time visibility, predictive insights, and operational efficiency all through The Single Interface™. Prevail InfoWorks unifies data from every system, every site, and every study into one intelligent view driven by AI-driven analytics that transform trial oversight and decision-making. Let’s talk about how you can bring greater speed, clarity, and confidence to your trials. Will you be at OCT New England this year? Arena International Events Group #ClinicalTrials #ClinicalResearch #ClinicalOperations #LifeSciences #Biotech #Pharma #ClinicalInnovation #DataIntegration #OCTNewEngland #PrevailInfoWorks

TCG Crossover Raises $1.3B for Its Third Biotech Investment Fund Over Four Years TCGX has closed its third fund in about four years, securing $1.3 billion and bringing its total capital under management to $3.1 billion. The round was backed by a mix of existing and new institutional, foundation, and endowment investors. Company leadership emphasized that surpassing their target demonstrates deep investor confidence in their strategy to back bold biotech innovation. Key Points • The new fund exceeds TCGX’s second fund, which closed with $1 billion • TCGX has backed high-profile biotech startups across multiple therapeutic areas • As part of their latest move, Giuliano Marostica was promoted to managing partner Questions How does this latest fund reflect continued confidence in biotech innovation? What factors are driving sustained investment momentum across life sciences? “Exceeding our target for Fund III highlights the deep trust and conviction our investors have placed in our team and approach.” Chen Yu, M.D., founder and managing partner of TCGX, said in the release. Read the full article in the comment section #Biotech #VentureCapital #TCG #LifeSciences #Innovation #HealthcareInvesting #DrugDevelopment #Research #PrevailInfoWorks #CapitalGrowth

October is for Her: Breast Cancer Awareness Month  Behind every data point, every study, and every milestone in breast cancer research there’s a woman, a family, and a story. At Prevail InfoWorks, we’re reminded that progress in oncology isn’t just about science. It is about people. It’s about mothers, sisters, daughters, and friends whose courage drives innovation forward. This month, we stand with the women who are fighting, the survivors who continue to inspire, and the countless individuals working tirelessly to advance breast cancer care and discovery. To those fighting, surviving, researching, and supporting: we see you. Your courage moves science forward. Your stories give meaning to every step toward better care. Here’s to awareness, early detection, and the hope that drives it all. How are you honoring or supporting Breast Cancer Awareness Month this year? #BreastCancerAwarenessMonth #BreastCancerAwareness #WomenInHealthcare #OncologyResearch #ClinicalResearch #HealthTech #LifeSciences #PatientCenteredCare #HopeInProgress #TogetherWePrevail #PrevailInfoWorks

Sanofi injects $625M into biotech innovation through Sanofi Ventures Big pharma is doubling down on biotech innovation. Sanofi just committed $625 million to its investment arm Sanofi Ventures raising its total assets to $1.4 billion. This infusion comes at a time when biotech funding is tight, but scientific innovation remains strong. Sanofi is betting big on today’s breakthroughs and tomorrow’s frontiers. Key highlights:  -Focus areas: immunology, rare diseases, neurology, and vaccines  -Expanding into emerging spaces: longevity, neuropsychiatry, ophthalmology, and pain  -Evergreen investment model returns are reinvested for long-term impact  -Global and stage-agnostic investment approach  By supporting biotechs worldwide, Sanofi is signaling confidence in the future of science-led healthcare transformation. Will this capital help accelerate breakthroughs in underfunded areas? Which “future core” areas hold the most promise longevity, neuropsychiatry, pain, or something else? “With a proven track record of strategic wins and successful exits, Sanofi Ventures has become a powerful engine for scientific progress and strategic growth,” Sanofi CEO Paul Hudson said in the release.   Read more in the comment section #Biotech #HealthcareInnovation #Pharma #VentureCapital #Immunology #RareDisease #Neurology #Vaccines #DigitalHealth #LifeSciences #PrevailInfoWorks #PrevailPartners 

GSK Commits $30 Billion to U.S. R&D, Biologics, and Manufacturing Expansion GSK has unveiled plans to invest $30 billion over the next five years in U.S. R&D, manufacturing, and supply chain infrastructure. The initiative includes a new $1.2 billion biologics facility in Upper Merion, Pennsylvania, as well as upgrades across sites in Maryland, North Carolina, and Montana. This large-scale investment underscores GSK’s commitment to strengthening U.S. pharmaceutical innovation, advancing biologics, and enhancing resilience against supply chain challenges. Flex Factory: Modular, AI-driven, Advanced Automation & Digital Integration - Built with interchangeable modules that can be easily reconfigured to support different manufacturing processes - Supports the production of various biologics, including antibodies, therapeutic proteins, and vaccines - Manufacture several biologic drugs at once or switch between them quickly, which is ideal for diverse therapeutic pipelines Question Is J.I.T. the new frontier for AI in supply chain logistics? Philadelphia, PA headquartered Prevail InfoWorks resolves global supply chain issues deploying The Single Interface™ to harness, consolidate, and reconcile data into a single sign on, role-based, unified view. AI and SAAS combine to automate, empowering Just-In-Time supply and management, without manual intervention. “This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both.” — Emma Walmsley, CEO of GSK Read the full article in the comment section below #GSK #Biotech #ClinicalTrials #Pharma #LifeSciences #DrugDevelopment #Manufacturing #SupplyChain #Innovation #FDA #Healthcare #PrevailInfoWorks #Prevail #InfoWorks #ArtificialIntelligence #AI #ClinicalDevelopment

Heading to the 13th Annual Outsourcing in Clinical Trials Southern California in San Diego on September 23–24? Clinical trials are only as strong as the processes and information that support them and that’s where many teams face setbacks. At Booth 10, you will see practical approaches powered by Prevail’s patented Single Interface™ that can help you: -Gain clear oversight across all your trial data in one place and never have to learn another system again -Spot risks and trends early with AI-driven insights into clinical and operational data  -Improve data quality and decision-making while reducing delays  -Streamline collaboration across sponsors, CROs, and sites  -Make manual reconciliation obsolete, removing reliance on spreadsheets Whether you are looking to strengthen study execution, accelerate timelines, or make trial management less complex, you will leave with new ideas to bring back to your team. Stop by at Prevail InfoWorks Booth 10 in San Diego to explore how smarter design, technology, and execution can benefit your upcoming studies. Arena International Events Group #ClinicalTrials #ClinicalResearch #LifeSciences #Biotech #Pharma #CRO #ClinicalInnovation #DataDriven #TrialSuccess #SoCalEvents #Prevail #PrevailInfoWorks

Prevail InfoWorks Team Member Recognized for Published Contribution to Clinical Trial Safety Oversight and Advancing Research Excellence Angela Overton, MSc is one of the published authors of “The Essential Role of Medical Monitors in Clinical Trials,” recently released in Cureus Journal of Medical Science. The article emphasizes the indispensable role of Medical Monitors in safeguarding patient safety, ensuring regulatory compliance, and upholding scientific integrity in clinical research. Want to know her secret to being one of most popular PV experts in the field, relied upon by sponsors and CROs alike? Angela and her team can share their first-hand experience, the secrets of her successes with life sciences companies, perhaps even one like yours: -Define the responsibilities and value of Medical Monitors in clinical trials -Underscore the importance of independent safety oversight for trial integrity -Highlight case studies where proper monitoring improved outcomes -Contribute to best practices in regulatory alignment and patient protection How have you seen greater awareness of Medical Monitors improve trial success rates? What role should independent oversight play in the future of biotech innovation? “Independent medical monitoring is not a formality; it is a strategic pillar of credible, compliant, and ethical drug and device development.” You may have been searching for the most cost-effective safety system. Or perhaps it was one you could recommend to a sponsor client that makes your and their work life easier or more fruitful in ways you previously wished were possible, only now to find out about a more advanced safety database with more of the features you had been hoping a systems supplier was dialed into are available. Features like cross-study correlating historical, publication, competitor safety data to your ongoing newly generated safety data (to build your safety ’n’) or automatically integrating safety system data with your other study data to avoid leaving you with the unpleasant reality of manual reconciliation. #ClinicalResearch #EarlySafetySignalDetectionSystem #Biotech #Biotechnology #LifeSciences #PatientSafety #MedicalMonitors #SafetySpecialist #Pharmacovigilance #Compliance #SafetyDetection #SafetySignals #EarlyDetection #CrossStudySafety #DataCorrelations #ClinicalTrials #RealTimeMonitoring #HealthcareInnovation #Pharma #ResearchIntegrity #TeamAchievement #PrevailInfoWorks #Prevail #InfoWorks #AffordableInPhaseOneSafetySystems https://lnkd.in/eQtvV5X4

LB Pharma has broken the log jam of IPO’s by coming onto the public market scene, and in such a big way LB Pharmaceuticals Inc recently upsized its IPO to $285 million. This offered 19 million shares at $15 on Nasdaq under ticker “LBRX” the first biotech IPO since February. The raise will support the development of its oral schizophrenia candidate LB-102, as well as trials in bipolar disorder. This substantial raise extends LB’s cash runway into 2028. -Pipeline focus: LB-102 (a modified version of amisulpride) showed positive Phase 2 data.   -Allocation of proceeds: Major chunk to Phase 3 schizophrenia trial; additional funding for Phase 2 bipolar trial; rest for general corporate needs.   -Financial resilience: Prior cash headwinds (entered July with ~$14 million), leadership changes & layoffs. The IPO upsized from 16.7M to 19M shares. Given the strength of recent Phase 2 data, how confident are you that LB-102 can reshape treatment for schizophrenia and bipolar disorder? What does this IPO tell us about investor appetite for CNS-focused biotech right now? TCGX, Vida Ventures, LLC, Pontifax Venture Capital, Heather Turner Read the full article in the comment section #Biotech #IPO #CNSDrugs #Schizophrenia #PharmaInnovation #DrugDevelopment #InvestmentOpportunity #NASDAQ #Bipolar #DeepTrackCapital #BipolarDisease #BipolarDisorder #InfoWorks #Prevail #PrevailInfoWorks

Lung Cancer Trial Data That’s More Than Just a “Small” Win Merck and Daiichi Sankyo’s phase 2 trial of I-DXd (ifinatamab deruxtecan) in small cell lung cancer showed a 48.2% response rate. A result that stands out in a space where treatment options are scarce and response rates are usually much lower. -48.2% ORR in 137 pretreated small cell lung cancer patients  -Median progression-free survival: 4.9 months; median overall survival: 10.3 months  -Disease control rate: 87.6%, with a median duration of response of 5.3 months  -Safety profile consistent, no unexpected surprises (always a relief) Questions worth pondering:  -Could nearly half the patients responding be enough to fast-track approval?  -With intracranial activity hitting 46.2%, is I-DXd about to make some serious noise? “The important take-home message is that this is our registrational trial for the first approval of the drug I-DXd.” Ken Takeshita, R&D head, Daiichi said Read full article in the comment section #BiotechNews #ADC #LungCancer #ClinicalData #SmallCellLungCancer #PrevailInfoworks #Prevail